Your browser doesn't support javascript.
loading
Novel Small-Molecule PD-L1 Inhibitor Induces PD-L1 Internalization and Optimizes the Immune Microenvironment.
Sun, Chengliang; Yin, Mingxiao; Cheng, Yao; Kuang, Zean; Liu, Xiaojia; Wang, Gefei; Wang, Xiao; Yuan, Kai; Min, Wenjian; Dong, Jingwen; Hou, Yi; Hu, Lingrong; Zhang, Guoyu; Pei, Wenli; Wang, Liping; Sun, Yanze; Yu, Xinmiao; Xiao, Yibei; Deng, Hongbin; Yang, Peng.
Afiliação
  • Sun C; State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
  • Yin M; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
  • Cheng Y; Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
  • Kuang Z; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
  • Liu X; State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
  • Wang G; Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
  • Wang X; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
  • Yuan K; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
  • Min W; State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
  • Dong J; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
  • Hou Y; Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
  • Hu L; State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
  • Zhang G; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
  • Pei W; Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
  • Wang L; State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
  • Sun Y; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
  • Yu X; Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
  • Xiao Y; State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
  • Deng H; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
  • Yang P; Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
J Med Chem ; 66(3): 2064-2083, 2023 02 09.
Article em En | MEDLINE | ID: mdl-36579489
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Inibidores de Checkpoint Imunológico Limite: Humans Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Inibidores de Checkpoint Imunológico Limite: Humans Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China